DUBLIN, May 15, 2026
Keenova Therapeutics announced updated clinical findings on XIAFLEX® (collagenase clostridium histolyticum) for the treatment of Peyronie’s disease, with new data presented at the 2026 American Urological Association (AUA) Annual Meeting. The analysis focused on patients with ventral penile curvature, showing that the therapy’s effectiveness and safety profile were consistent with results observed in broader Peyronie’s disease populations. The study strengthens evidence supporting non-surgical treatment options for men affected by the condition, particularly those with complex curvature presentations.
The presentation, delivered by Jesse Mills, highlighted findings from a multicenter retrospective analysis evaluating collagenase clostridium histolyticum (CCH) therapy in ventral curvature cases. Researchers reported that outcomes remained aligned with previously published clinical studies, reinforcing the therapy’s role in reducing penile curvature and improving patient quality of life. The updated analysis also supports ongoing clinical research aimed at expanding understanding of Peyronie’s disease progression and long-term treatment management.
XIAFLEX Continues to Show Clinical Benefit
According to the study, XIAFLEX maintained encouraging safety and efficacy outcomes across patients with ventral penile curvature, a subgroup often associated with more complicated disease management. Researchers emphasized that treatment results were consistent with prior real-world and clinical trial evidence supporting collagenase-based therapy for Peyronie’s disease. Physicians involved in the analysis noted that many patients continue to seek alternatives to surgery, particularly therapies capable of improving curvature while preserving sexual function and minimizing recovery time.
Peyronie’s disease occurs when fibrous scar tissue develops inside the penis, causing abnormal curvature, pain, and difficulty during intimacy. Industry estimates suggest the disease may affect up to 1 in 10 men in the United States, although diagnosis rates remain relatively low due to patient discomfort discussing symptoms. The latest findings presented at AUA 2026 may help expand physician confidence in treating ventral curvature cases using minimally invasive biologic therapy approaches.
Safety Profile and Risk Considerations
Advertisement
Keenova also reiterated important safety information associated with XIAFLEX therapy, including the risk of corporal rupture, penile injury, hematoma, swelling, and hypersensitivity reactions. The treatment remains available only through the restricted XIAFLEX REMS Program because of these risks. Clinical trial data previously showed penile hematoma and swelling among the most commonly reported adverse reactions, while rare severe complications such as penile fracture and tissue injury have also been reported.
Despite these safety considerations, investigators stated that the updated data reinforce the benefit-risk profile of the therapy when administered appropriately. The company emphasized that treatment should be carefully managed by experienced healthcare providers trained in Peyronie’s disease injections and patient monitoring. Keenova believes the updated findings further position XIAFLEX as a leading biologic therapy option for men seeking effective, non-surgical management of Peyronie’s disease.
Source: Keenova Therapeutics press release
